Cara TenenbaumJD/MBA
Areas of Focus
Overview
Cara is a Consultant for Crowell Health Solutions and a seasoned health policy expert, advocate, and writer with almost two decades of health policy experience. That includes experience in the patient advocacy field, having been the head of policy for a small non-profit focusing on women's health. There, she handled all advocacy, including appropriations, authorizing legislation, drafting testimony, presenting testimony, preparing regulatory comment letters and working with all operating divisions of HHS, as needed. Additionally, she functioned as spokesperson for the organization, appearing on national and international TV as well as in print. Cara was at the FDA for six years, working in both the Office of External Affairs in the Commissioner's Office and the Office of the Center Director in the Center for Devices and Radiological Health. There, Cara worked on issues at the intersection of policy, legislation and advocacy, helping further the Agency's agenda with patient and provider groups.
Career & Education
- Case Western Reserve University, JD/MBA
- University of Maryland, College Park, B.A., Economics
Cara's Insights
Client Alert | 11 min read | 05.03.24
FDA Moves Forward on Laboratory Developed Tests while Stakeholders and Congress Weigh Next Steps
Digital health companies, investors, and other healthcare organizations should follow policy developments with a strategic lens towards their market opportunities for key potential growth and risk mitigation.
Blog Post | 12.26.23
FDA Releases Guidance on Digital Health Technologies for Clinical Investigations
Insights
Senate HELP Committee Ranking Member Issues Health Data Privacy Policy Recommendations
|04.18.24
Crowell Health Solution’s Trends in Transformation
FDA Releases Guidance on Digital Health Technologies for Clinical Investigations
|12.26.23
Crowell Health Solution’s Trends in Transformation
Practices
Industries
Cara's Insights
Client Alert | 11 min read | 05.03.24
FDA Moves Forward on Laboratory Developed Tests while Stakeholders and Congress Weigh Next Steps
Digital health companies, investors, and other healthcare organizations should follow policy developments with a strategic lens towards their market opportunities for key potential growth and risk mitigation.
Blog Post | 12.26.23
FDA Releases Guidance on Digital Health Technologies for Clinical Investigations